Nomograms predict the benefit of different therapeutic modalities for patients with early stage hepatocellular carcinoma

Yu Liu; Yu Liu; Jiaqu Cui; Jiaqu Cui; Xinchun Liu; Xinchun Liu; Huihui Sun; Huihui Sun; Zhaoming Zhou; Zhaoming Zhou; Ligong Lu; Ligong Lu; Bing Liu; Bing Liu

doi:10.18632/oncotarget.24011

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 01/08/2018.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Nomograms predict the benefit of different therapeutic modalities for patients with early stage hepatocellular carcinoma

Yu Liu _, Yu Liu, Jiaqu Cui, Jiaqu Cui, Xinchun Liu, Xinchun Liu, Huihui Sun, Huihui Sun, Zhaoming Zhou, Zhaoming Zhou, Ligong Lu, Ligong Lu, Bing Liu and Bing Liu _

Yu Liu1,*, Jiaqu Cui2,*, Xinchun Liu2, Huihui Sun2, Zhaoming Zhou2, Ligong Lu3 and Bing Liu2,3

1 Department of Infection, The Second Hospital of Dalian Medical University, Dalian, P.R. China

2 Department of Surgery, Heidelberg University Hospital, Heidelberg, Germany

3 Cancer Center, Zhuhai People’s Hospital, Zhuhai, P.R. China

* These authors contributed equally to this work

Correspondence to:

Bing Liu, email: [email protected]

Keywords: nomogram; SEER; hepatocellular carcinoma; radiofrequency ablation; curative resection

Received: July 11, 2017 Accepted: December 26, 2017 Epub: January 8, 2018

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24011

Publication Alerts

2024 SSP Annual Meeting

Withdrawal Notice

Research Papers:

Nomograms predict the benefit of different therapeutic modalities for patients with early stage hepatocellular carcinoma